Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.
Pasricha
Pankaj Jay
PJ
University of Texas Medical Branch, Gasveston, TX 77555, USA. jpasrich@utmb.edu
D017277:Drug Approval; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D043183:Irritable Bowel Syndrome / Q000188:drug therapy; D007511:Ischemia / Q000139:chemically induced; D008389:Marketing of Health Services; D017366:Serotonin Receptor Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000639:trends*; D014481:United States
D005765:Gastrointestinal Agents; D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod